Achieved record 2025 revenue of $201 million, driven by a 22% increase in U.S. physician adoption and expanded utilization across the sacropelvic platform. Transitioned to a sustainable financial profile, delivering the first full year of positive adjusted EBITDA and reaching positive free cash flow in the fourth quarter. Leveraged a hybrid sales model to drive territory productivity to $2.1 million per manager, an 18% year-over-year increase. Strengthened market leadership in the thoracolumbar spac ...

Profitability improved as the company delivered its first full year of positive Adjusted EBITDA. Gross margin was 79% in the fourth quarter and 79.6% for the full year, with Maheshwari noting the full-year gross margin came in about 200 basis points above the company’s original 2025 guidance. He attributed the outperformance to stable average selling prices from favorable procedure mix and to operational initiatives such as supply chain efficiency and cost optimization.For the full year 2025, worldwide reve ...

Core Viewpoint - The current market trend is moving away from heavily shorted growth stocks, but there remains potential for contrarian investors to capitalize on short squeezes by identifying stocks that may rebound [1]. Group 1: Shorted Stocks Analysis - A screening process identifies stocks where short sellers might incur significant losses, indicating a potential for covering their positions [2]. - The analysis involves reviewing short interest reports from the past year to determine when shorts were added and estimating their average entry price based on prior performance [3]. Group 2: Notable Stocks with High Short Interest - Significant stocks with high short interest include: - AST SpaceMobile (ASTS) with a last close of $96.92 and a short interest percentage of 18.0%, showing a 225% increase in short interest [4]. - IREN, a data center company, with a last close of $42.67 and a short interest percentage of 12.8%, reflecting a 3929% increase [4]. - Oklo (OKLO), a nuclear energy startup, with a last close of $66.23 and a short interest percentage of 13.6%, indicating a staggering 5887% increase [4]. - Other notable mentions include: - APLD in digital assets with a last close of $36.60 and a short interest percentage of 36.9%, showing a 418% increase [4]. - SEI in investment banking with a last close of $53.73 and a short interest percentage of 27.9%, reflecting a 2348% increase [4].

分组1 - Electromed, Inc. reported quarterly earnings of $0.32 per share, exceeding the Zacks Consensus Estimate of $0.27 per share, and showing an increase from $0.22 per share a year ago, resulting in an earnings surprise of +20.76% [1] - The company achieved revenues of $18.9 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 4.40%, and up from $16.25 million year-over-year [2] - Electromed has surpassed consensus EPS estimates three times over the last four quarters, indicating a positive trend in earnings performance [2] 分组2 - The stock has underperformed the market, losing about 5.2% since the beginning of the year, while the S&P 500 has gained 1.7% [3] - The current consensus EPS estimate for the upcoming quarter is $0.26 on revenues of $17.54 million, and for the current fiscal year, it is $1.07 on revenues of $71.61 million [7] - The Medical - Instruments industry, to which Electromed belongs, is currently ranked in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Company Overview - SI-BONE, Inc. (NASDAQ:SIBN) develops and sells medical devices targeting musculoskeletal disorders in the sacropelvic area, including minimally invasive implants for sacroiliac joint dysfunction, pelvic trauma, and spinal support [2]. Investment Sentiment - The company has been highlighted as a speculative investment opportunity, with notable interest from investment commentators, indicating a growing recognition in the market [1]. - There is a suggestion that while SI-BONE has potential, certain AI stocks may offer greater upside potential and carry less downside risk, indicating a competitive investment landscape [3].

Core Insights - SI-Bone Inc. (NASDAQ:SIBN) shares experienced a 3.65% increase in after-hours trading, closing at $21.14, following a regular trading session close of $20.40, which was up 2.15% [1] Executive Share Sales - Three executives sold shares to cover tax obligations from restricted stock unit vesting, with Chief Financial Officer Anshul Maheshwari selling 5,229 shares for a total of $102,710.61 [2] - Senior Vice President and Chief Legal Officer Michael Pisetsky sold 3,460 shares totaling $67,896.05, while President of Commercial Operations Anthony Recupero sold 3,677 shares for $72,143.84 [3] Trading Metrics and Performance - SI-Bone has a Relative Strength Index (RSI) of 62.48 and a 12-month return of 44.48%, indicating strong performance and an upward trend [5] - The company's market capitalization is approximately $885.2 million, with shares trading between a 52-week high of $21.06 and a low of $12.50 [5] - Currently, SIBN is trading at 92.2% of its 52-week range, suggesting it is near its annual highs [6] Analyst Ratings - Analysts from Truist Securities, Canaccord Genuity, Needham & Company, and Morgan Stanley have maintained bullish ratings and raised price targets for SIBN [6] - Benzinga's Edge Stock Rankings indicate a positive price trend for SIBN across all time frames [7]

Core Viewpoint - Needham analyst David Saxon has raised the price target for SI-Bone (SIBN) to $27 from $24 while maintaining a Buy rating on the shares, indicating confidence in the company's growth potential [1] Group 1: Price Target and Ratings - The price target for SI-Bone has been increased to $27 from $24 [1] - SI-Bone has been added to Needham's 'Conviction List' and is named as the firm's '2026 Top Pick' [1] Group 2: Growth Potential - Needham believes SI-Bone can deliver potential upside to estimates in the near term, which is expected to enhance profitability [1] - Upcoming product launches are anticipated to drive active surgeon adoption across SI-Bone's portfolio, leading to higher utilization [1]

Core Insights - Treace Medical Concepts reported a quarterly loss of $0.26 per share, which was better than the Zacks Consensus Estimate of a loss of $0.28, representing an earnings surprise of +7.14% [1] - The company achieved revenues of $50.21 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 1.27% and showing an increase from $45.09 million in the same quarter last year [2] - Treace Medical Concepts has consistently surpassed consensus EPS and revenue estimates over the last four quarters [2] Financial Performance - The company has reported a loss of $0.26 per share compared to a loss of $0.25 per share a year ago, indicating a slight deterioration year-over-year [1] - The stock has underperformed, losing about 16% since the beginning of the year, while the S&P 500 has gained 15.6% [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is breakeven on revenues of $77.57 million, while for the current fiscal year, it is projected at -$0.81 on revenues of $227.1 million [7] - The Zacks Rank for Treace Medical Concepts is currently 3 (Hold), suggesting that the shares are expected to perform in line with the market in the near future [6] Industry Context - The Medical - Instruments industry, to which Treace Medical Concepts belongs, is currently in the top 35% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Treace Medical Concepts' stock performance [5]

Financial Performance - PROCEPT BioRobotics Corporation reported a quarterly loss of $0.38 per share, which was better than the Zacks Consensus Estimate of a loss of $0.41, representing an earnings surprise of +7.32% [1] - The company posted revenues of $83.33 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 3.35% and showing a significant increase from $58.37 million in the same quarter last year [2] Stock Performance - PROCEPT BioRobotics shares have declined approximately 57.1% since the beginning of the year, contrasting with the S&P 500's gain of 16.5% [3] - The current Zacks Rank for PROCEPT BioRobotics is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The consensus EPS estimate for the upcoming quarter is -$0.25 on revenues of $96.42 million, and for the current fiscal year, it is -$1.48 on revenues of $325.4 million [7] - The trend of estimate revisions for PROCEPT BioRobotics was mixed ahead of the earnings release, which could change following the recent report [6] Industry Context - The Medical - Instruments industry, to which PROCEPT BioRobotics belongs, is currently ranked in the top 38% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Core Insights - SI-BONE, Inc. will report its financial results for Q1 2025 on May 5, 2025, after market close, with a conference call scheduled for 1:30 p.m. Pacific Time [1] - The company is a leader in developing technologies for surgical treatment of sacropelvic disorders, having supported over 4,300 physicians and performed over 115,000 procedures since 2009 [3] Company Overview - SI-BONE has pioneered minimally invasive SI joint surgery and has a strong clinical evidence base, including two randomized controlled trials and over 160 peer-reviewed publications [3] - The company has expanded its offerings to adjacent markets, including adult deformity, sacropelvic fixation, and pelvic trauma [3] Investor Information - Investors can listen to the conference call by registering online, and a live audio webcast will be available on the company's website [2] - The webcast will be archived for at least 90 days for replay [2]